X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs CADILA HEALTHCARE - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS CADILA HEALTHCARE NOVARTIS/
CADILA HEALTHCARE
 
P/E (TTM) x 348.2 20.1 1,730.9% View Chart
P/BV x 38.6 4.8 809.5% View Chart
Dividend Yield % 1.2 0.9 137.8%  

Financials

 NOVARTIS   CADILA HEALTHCARE
EQUITY SHARE DATA
    NOVARTIS
Mar-18
CADILA HEALTHCARE
Mar-18
NOVARTIS/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs758558 135.8%   
Low Rs579362 160.2%   
Sales per share (Unadj.) Rs228.4116.3 196.4%  
Earnings per share (Unadj.) Rs31.717.9 177.6%  
Cash flow per share (Unadj.) Rs32.823.1 141.6%  
Dividends per share (Unadj.) Rs10.003.50 285.7%  
Dividend yield (eoy) %1.50.8 196.5%  
Book value per share (Unadj.) Rs297.185.4 347.9%  
Shares outstanding (eoy) m24.691,023.74 2.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.94.0 74.0%   
Avg P/E ratio x21.125.7 81.9%  
P/CF ratio (eoy) x20.419.9 102.7%  
Price / Book Value ratio x2.25.4 41.8%  
Dividend payout %31.519.6 160.9%   
Avg Mkt Cap Rs m16,505470,664 3.5%   
No. of employees `0000.711.8 5.7%   
Total wages/salary Rs m1,44518,545 7.8%   
Avg. sales/employee Rs Th8,441.310,072.7 83.8%   
Avg. wages/employee Rs Th2,163.61,569.1 137.9%   
Avg. net profit/employee Rs Th1,173.11,547.7 75.8%   
INCOME DATA
Net Sales Rs m5,639119,049 4.7%  
Other income Rs m1,7181,132 151.8%   
Total revenues Rs m7,357120,181 6.1%   
Gross profit Rs m-6328,475 -0.2%  
Depreciation Rs m255,388 0.5%   
Interest Rs m55911 6.1%   
Profit before tax Rs m1,57523,308 6.8%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7925,644 14.0%   
Profit after tax Rs m78418,292 4.3%  
Gross profit margin %-1.123.9 -4.6%  
Effective tax rate %50.324.2 207.5%   
Net profit margin %13.915.4 90.4%  
BALANCE SHEET DATA
Current assets Rs m9,52282,005 11.6%   
Current liabilities Rs m3,29660,720 5.4%   
Net working cap to sales %110.417.9 617.5%  
Current ratio x2.91.4 213.9%  
Inventory Days Days3773 50.1%  
Debtors Days Days2898 28.9%  
Net fixed assets Rs m4683,703 0.1%   
Share capital Rs m1231,024 12.1%   
"Free" reserves Rs m7,21386,421 8.3%   
Net worth Rs m7,33687,445 8.4%   
Long term debt Rs m025,551 0.0%   
Total assets Rs m11,105180,653 6.1%  
Interest coverage x29.526.6 110.9%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.50.7 77.1%   
Return on assets %7.610.6 71.1%  
Return on equity %10.720.9 51.1%  
Return on capital %22.222.0 101.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6142,683 0.1%   
Fx outflow Rs m3,63011,242 32.3%   
Net fx Rs m-3,57031,441 -11.4%   
CASH FLOW
From Operations Rs m1,6109,193 17.5%  
From Investments Rs m687-9,737 -7.1%  
From Financial Activity Rs m-2,677515 -519.7%  
Net Cashflow Rs m-380-29 1,309.0%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 8.3 24.1%  
FIIs % 1.6 5.9 27.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 11.0 195.5%  
Shareholders   41,647 44,069 94.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   DR. REDDYS LAB  STERLING BIOTECH  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  IPCA LABS  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Sep 19, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS